New filler takes on juvederm for wrinkle reduction
NCT ID NCT06509477
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a new dermal filler called Lunaphil Ultra works as well as the established Juvederm Ultra 4 for treating moderate to severe nasolabial folds (smile lines). 104 adults received one filler on one side of the face and the other on the opposite side, with results measured by wrinkle severity and aesthetic improvement. The goal was to see if Lunaphil Ultra is a safe and effective alternative.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Hyaluronic acid dermal filler (Lunaphil Ultra or Juvederm Ultra 4)
- What this could lead to
- If successful, this could show that Lunaphil Ultra is a safe and effective alternative to Juvederm for reducing deep smile lines.
- What could go wrong
- This is a small, completed equivalency study, not a large phase 3 trial. Results may not apply to all skin types or other wrinkles, and individual results vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
104 people
The number who actually took part.
- Started
-
Dec 2021
- Finished
-
Nov 2023
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects ≥ 30 years of age * Visible bilateral NLFs that were approximately symmetrical and had an equal severity ranging from moderate to severe (assessed at the deepest part) * Able to follow study instructions and likely to complete all required visits * Signed informed consent Exclusion Criteria: * History of bleeding disorders or participants receiving or recently exposed (≤ 3 weeks) to continuous treatment with thrombolytics, anticoagulants, platelet inhibitors, or NSAIDs * Acute herpetic eruption * Known susceptibility to keloid formation, hypertrophic scarring or clinically significant skin pigmentation disorders * Known sensitivity to local anesthetics of the amide type (such as lidocaine), history of hypersensitivity to gram-positive bacterial proteins, history of multiple severe allergies, history of anaphylactic shock * Known hypersensitivity to any component of the study products or excipients (like hyaluronic acid) * History of receiving immune therapy or a history of autoimmune disease * History of active chronic debilitating systemic disease * History of connective tissue disease, history of malignancy (except for non-melanoma skin cancer) within the last 5 years * Clinically significant active dermatologic disorders within the last 6 months * Use of oral retinoids, over-the-counter (OTC) or prescription antiwrinkle treatments, microdermabrasion, or chemical peels in the NLF area within the last 4 weeks or intention to use them during the study * Any prior cosmetic procedure or tissue augmentation at the NLF injection site within 1 year before study entry (or intent to undergo such a procedure during the study) * Pregnancy or breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Moderate or severe nasolabial folds are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Orchid Pharmed, Medical Department
Tehran, 19947-66411, Iran